指南与共识神经肿瘤

在有IDH突变且CDKN2A/B无纯合缺失的星形细胞瘤中,核分裂计数具有预后价值:EORTC 26053(CATNON)与EORTC 22033-26033试验共识专家组复核结果

Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
指南 / 共识 · Neuro Oncol · 2023-01-01

由7名神经病理学家组成的国际专家组,对EORTC 22033-26033试验中192例低级别胶质瘤和EORTC 26053(CATNON)试验中263例1p19q非共缺失间变性胶质瘤的IDH突变星形细胞瘤虚拟显微图像,按13项明确界定的组织学特征评分;共识组织学特征与CDKN2A/B纯合缺失联合检验独立预后价值。核分裂计数(阈值:每10个高倍视野2个核分裂,标准化视野直径0.55 mm、面积0.24 mm²)显著影响无进展生存(P=0.0098),对总生存影响边缘(P=0.07)。

要点

  • 核分裂计数阈值为每10个高倍视野2个核分裂(视野直径0.55 mm、面积0.24 mm²)。
  • 核分裂计数显著影响无进展生存(P=0.0098),对总生存影响边缘(P=0.07)。
  • 核分裂计数也显著影响CDKN2A/B纯合缺失肿瘤的无进展生存,对总生存无显著影响。

核心结论

  • 在无CDKN2A/B纯合缺失的IDH突变星形细胞瘤中,核分裂指数(阈值每10个40×高倍视野2个)具有预后意义。
  • 作者认为核分裂指数可能指导CDKN2A/B原生状态IDH突变星形细胞瘤患者的治疗策略。

研究设计与样本

  • 国际专家组由7名神经病理学家组成,对EORTC 22033-26033试验的192例低级别胶质瘤和EORTC 26053(CATNON)试验的263例1p19q非共缺失间变性胶质瘤的IDH突变星形细胞瘤虚拟显微图像评分13项明确界定的组织学特征。
  • 192例胶质瘤的CDKN2A/B状态已知。
  • 共识组织学特征(专家组至少4/7同意)与CDKN2A/B纯合缺失联合检验独立预后价值。

主要发现

  • 共识组织学参数中,核分裂计数(阈值每10个高倍视野2个核分裂,标准化视野直径0.55 mm、面积0.24 mm²)显著影响无进展生存(P=0.0098),对总生存影响边缘(P=0.07)。
  • 核分裂计数也显著影响CDKN2A/B纯合缺失肿瘤的无进展生存,但对总生存无显著影响,可能因随访数据有限。

关键数值与推荐

  • 核分裂计数阈值为每10个高倍视野2个核分裂,标准化视野直径0.55 mm、面积0.24 mm²。
  • 核分裂计数对无进展生存的P=0.0098,对总生存的P=0.07。
  • 共识定义为专家组至少4/7同意。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 核分裂计数对总生存仅边缘影响(P=0.07)。
  • 核分裂计数对CDKN2A/B纯合缺失肿瘤的总生存无显著影响,可能因随访数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliomas with IDH1/2 mutations without 1p19q codeletion have been identified as the distinct diagnostic entity of IDH mutant astrocytoma (IDHmut astrocytoma). Homozygous deletion of Cyclin-dependent kinase 4 inhibitor A/B (CDKN2A/B) has recently been incorporated in the grading of these tumors. The question of whether histologic parameters still contribute to prognostic information on top of the molecular classification, remains unanswered. Here we evaluated consensus histologic parameters for providing additional prognostic value in IDHmut astrocytomas. METHODS: An international panel of seven neuropathologists scored 13 well-defined histologic features in virtual microscopy images of 192 IDHmut astrocytomas from EORTC trial 22033-26033 (low-grade gliomas) and 263 from EORTC 26053 (CATNON) (1p19q non-codeleted anaplastic glioma). For 192 gliomas the CDKN2A/B status was known. Consensus (agreement ≥ 4/7 panelists) histologic features were tested together with homozygous deletion (HD) of CDKN2A/B for independent prognostic power. RESULTS: Among consensus histologic parameters, the mitotic count (cut-off of 2 mitoses per 10 high power fields standardized to a field diameter of 0.55 mm and an area of 0.24 mm2) significantly influences PFS (P = .0098) and marginally the OS (P = .07). Mitotic count also significantly affects the PFS of tumors with HD CDKN2A/B, but not the OS, possibly due to limited follow-up data. CONCLUSION: The mitotic index (cut-off 2 per 10 40× HPF) is of prognostic significance in IDHmut astrocytomas without HD CDKN2A/B. Therefore, the mitotic index may direct the therapeutic approach for patients with IDHmut astrocytomas with native CDKN2A/B status.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kros JM, Rushing E, Uwimana AL, et al. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Neuro Oncol. 2023. PMID: 36571817. doi:10.1093/neuonc/noac282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。